Search

Buclizine

[A178102] In addition to the above conditions, buclizine has been studied in the treatment of migraine attacks and in the treatment of nausea and vomiting during pregnancy. [A178105, A178108] … [L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated.

Dornase alfa

The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. … Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity.

Deoxycholic acid

In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. … It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical

Neostigmine

A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. … Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.

Adagrasib

[A254941] However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding … [L43847] In December 2022, the FDA granted accelerated approval to adagrasib for the treatment of KRAS^G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic

Probucol

A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).

Durlobactam

[L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. … It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.

Rofecoxib

Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. … This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety.

Sebelipase alfa

This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction. … The lysosomal acid lipase (LAL) enzyme is found in lysosomes and is primarily responsible for the metabolism of lipids, and its absence or deficiency results in the accumulation of lipids in various organs

Niacinamide ascorbate